



Dkt No. 2251/75190/JPW/BJA/CSA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Stan Gronthos et al.

Serial No. : 10/551,162                      Group Art Unit: 1644

Filed : March 29, 2004              Examiner: Michail A.  
Belyavskyi

Title : PERIVASCULAR MESENCHYMAL PRECURSOR CELLS

30 Rockefeller Plaza, 20<sup>th</sup> Fl.  
New York, New York 10112  
July 26, 2010

MAIL STOP RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

07/29/2010 SDENBOB3 00000028 10551162

01 FC:2255

1175.00 OP

Sir:

**AMENDMENT IN RESPONSE TO JUNE 22, 2009 FINAL OFFICE ACTION,  
AND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
AS SUBMISSIONS UNDER 37 C.F.R. §1.114(C)  
TO THE ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION  
AND PETITION FOR FIVE-MONTH EXTENSION OF TIME**

This Amendment is a submission under 37 C.F.R. §1.114(c) to accompany a Request for Continued Examination (RCE) and responds to the rejections in the June 22, 2009 Final Office Action issued by the U.S. Patent and Trademark Office in connection with the above-identified application. Applicants filed a Notice of Appeal and a Petition for Three-month Extension of Time on December 22, 2009, which was stamped as received by the OIPE on December 29, 2009. Accordingly, an Appeal Brief was due on February 28, 2010. Applicants hereby petition for a five-month extension of time. The fee for a five-month extension of time for a small entity is ONE THOUSAND ONE HUNDRED AND SEVENTY FIVE DOLLARS (\$1,175.00),

Applicants: Stan Gronthos et al.  
Serial No.: 10/551,162  
Filed: March 29, 2004  
Page 2

and a check for this amount is enclosed. With a five-month extension of time, a response is now due July 28, 2010. Accordingly, the RCE, and this Amendment and Supplemental Information Disclosure Statement as submissions to accompany the RCE, are being timely filed.

Please amend the subject application as follows:

**Amendment to the claims** begins on page 3 of this paper.

**Remarks** begin on page 6 of this paper.

**The Supplemental Information Disclosure Statement** begins on page 15 of this paper.